Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

Abstract

BACKGROUND Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis. METHODS We concluded a randomized trial involving 1088 patients with multiple sclerosis, 18 to 55 years of age, with a score of 0 to 5.5 on the Expanded Disability Status Scale and at least one relapse in the previous year or at least two relapses… (More)
DOI: 10.1056/NEJMoa1014656

4 Figures and Tables

Topics

  • Blog articles referencing this paper

  • Presentations referencing similar topics